ArticleFrontiers in psychiatry2021
COVID-19 in People With Schizophrenia: Potential Mechanisms Linking Schizophrenia to Poor Prognosis.
Article in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mortality from coronavirus disease 2019 (Covid-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression.General hospital psychiatryPooled it
- Covid-19 a Strong Predictor of Hyperglycaemia Among Ugandan Patients: A Retrospective Study.Research square · 2026Article
- Severe Outcomes and Length of Stay Among People With Schizophrenia Hospitalized for COVID-19: A Population-Based Retrospective Cohort Study.Schizophrenia bulletin · 2026Article
- What is behind the 17-year life expectancy gap between individuals with schizophrenia and the general population?Schizophrenia (Heidelberg, Germany) · 2025Article
- Dual inflammation in schizophrenia infected with COVID-19: Impact on cognitive function.Brain, behavior, & immunity - health · 2025Article
- Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study.Human vaccines & immunotherapeutics · 2024Article
- Causes and countermeasures for the increased infection and COVID-19 mortality rates in patients with schizophrenia.IBRO neuroscience reports · 2024Review
- Treatment of Cognitive Impairment Associated with Schizophrenia Spectrum Disorders: New Evidence, Challenges, and Future Perspectives.Brain sciences · 2024Review
- Global research in schizophrenia and serotonin: a bibliometric analysis.Frontiers in psychiatry · 2024Review
- Symptom Exacerbations of Patients Attending a Community Mental Health Center During the COVID-19 Pandemic.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2024Article
- Attitudes toward COVID-19 pandemic measures and clinical symptom severity in schizophrenia patients: a preliminary cross-sectional study.The Journal of international medical research · 2023Article
- Changes in Quality of Life in Treatment-Resistant Schizophrenia Patients Undergoing Avatar Therapy: A Content Analysis.Journal of personalized medicine · 2023Article
- Psychiatric symptoms before and after COVID-19 vaccination: A cohort study of hospitalized schizophrenia patients.Asian journal of psychiatry · 2022Article
- Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting.Psychiatry research · 2022Observational
- Medium-term and peri-lockdown course of psychosocial burden during the ongoing COVID-19 pandemic: a longitudinal study on patients with pre-existing mental disorders.European archives of psychiatry and clinical neuroscience · 2022Article
- [COVID-19 vaccinations in institutions for forensic commitment: some considerations on ethical and medico-legal aspects].Der Nervenarzt · 2022Article
- Immune Response Is Key to Genetic Mechanisms of SARS-CoV-2 Infection With Psychiatric Disorders Based on Differential Gene Expression Pattern Analysis.Frontiers in immunology · 2022Article
- Challenges and Insights From Treating Psychotic Disorders During COVID-19 Pandemic in Brazil.Schizophrenia bulletin open · 2022Review
- The role of psychological autopsy in investigating a case of atypical suicide in schizophrenia: a case report with a brief review of literature.Egyptian journal of forensic sciences · 2022Article
- COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review.Frontiers in psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
As the global burden of mortality from COVID-19 continues to rise, an understanding of who is most at risk of adverse outcomes is of paramount importance. Pre-existing cardiometabolic, renal and respiratory diseases as well as old age are well-established risk factors associated with disease severity and mortality among patients with COVID-19. However, mounting evidence also indicates an increased susceptibility to, and risk of adverse outcomes from COVID-19 in people with schizophrenia, independent of age and comorbidity. Therefore, elucidating the underlying pathophysiological mechanisms which may increase the risk of poor outcomes in people with schizophrenia is of crucial importance. Here, we provide a narrative on the current understanding of COVID-19 in patients with schizophrenia and propose potential mechanisms which may link schizophrenia with an increased susceptibility to, and greater risk of adverse outcomes from COVID-19. Given the existing knowledge gaps, robust clinical and biological studies are required to further our understanding of some of these underlying mechanisms, so that effective prevention and treatment strategies for COVID-19 in patients with schizophrenia can be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.